Does this mean I should choose surgery over GLP-1 medications?

Not necessarily. Surgery carries more risks and may not be suitable for everyone, especially older patients. Speak with your doctor to weigh the benefits and risks based on your age, health history, and personal goals.

Which GLP-1 medications were studied?

The study looked at weekly injectable semaglutide (brand names Ozempic or Wegovy) and tirzepatide (brand names Mounjaro or Zepbound).

Were these results the same for all racial and ethnic groups?

The study noted demographic differences — surgery patients were more likely to be Hispanic and younger, while medication users were more likely to be white and older. Researchers adjusted for these differences in their analysis.

Bariatric Surgery vs. GLP-1 Drugs for Diabetes Weight Loss

Key takeaways

✓Bariatric surgery produced nearly 23% total body weight loss over 3 years — significantly more than GLP-1 medications
✓Even patients who stayed on GLP-1 drugs for a full year lost less weight than surgery patients at every time point
✓This is one of the first large studies focused specifically on Medicare and Medicaid patients, representing real-world publicly insured Americans

Quick specs

Journal	Surgical endoscopy
Year	2026
PMID	41326727

What This Study Looked At

Researchers compared two popular treatments for obesity and type 2 diabetes: bariatric (weight-loss) surgery and GLP-1 receptor agonist medications — including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). The study focused on Medicare and Medicaid patients, who make up the largest group of publicly insured Americans.

Who Was Included?

The study followed 7,667 adults with type 2 diabetes and a BMI over 35 between 2018 and 2024. Of these:

7,200 used GLP-1 medications
467 had bariatric surgery

Surgery patients tended to be younger (average age 43) compared to medication users (average age 65). More surgery patients were Hispanic, while more medication users were white.

What Did They Find?

After 3 years, the results showed a major difference in weight loss:

Bariatric surgery: ~22.9% total body weight lost
Any GLP-1 medication use: ~2.3% total body weight lost
12 months of continuous GLP-1 use: ~15.9% lost (surgery) vs. ~2.4% (medication)

Surgery outperformed GLP-1 medications at every time point measured, from 3 months all the way through 3 years.

Why the Big Difference in Medication Results?

One important factor: many patients did not stay on their GLP-1 medication consistently. When researchers looked only at patients who took the medication for at least 12 consecutive months, weight loss improved — but surgery still came out ahead.

What This Means for You

If you have type 2 diabetes, obesity, and are covered by Medicare or Medicaid, this study suggests that bariatric surgery may offer greater long-term weight loss than GLP-1 medications. However, surgery carries its own risks and isn't right for everyone. Talk to your doctor about which option best fits your health needs, age, and personal preferences.

References & Sources

Frequently asked questions

Many patients did not take their medication consistently. When only those who used GLP-1 drugs for 12 straight months were counted, weight loss improved to about 15.9% — but surgery still outperformed them.

Editorial note

This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management. Last reviewed: July 16, 2026 by the MDS Diabetes editorial team.

What to do next

📚

Surgery vs. GLP-1 Drugs: Which Works Better Long-Term?